Similar articles

• Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.

  Carlo-Stella C, Mangoni L, Almici C, Cottafavi L, Meloni G, Mandelli F, Rizzoli V. Carlo-Stella C, et al. Blood. 1992 Nov 1;80(9):2412-8. Blood. 1992. PMID: 1421413 Clinical Trial.
• In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.

  Carlo-Stella C, Mangoni L, Piovani G, Almici C, Garau D, Caramatti C, Rizzoli V. Carlo-Stella C, et al. Bone Marrow Transplant. 1991 Oct;8(4):265-73. Bone Marrow Transplant. 1991. PMID: 1756324
• Recombinant human granulocyte-macrophage colony stimulating factor (rh GM-CSF) after bone marrow transplantation.

  Link H, Freund M, Kirchner H, Stoll M, Schmid H, Bucsky P, Seidel J, Schulz G, Schmidt RE, Riehm H, et al. Link H, et al. Behring Inst Mitt. 1988 Aug;(83):313-9. Behring Inst Mitt. 1988. PMID: 3071346
• A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation.

  Barge AJ. Barge AJ. Bone Marrow Transplant. 1993;11 Suppl 2:1-11. Bone Marrow Transplant. 1993. PMID: 8334433 Review.
• The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.

  Nemunaitis JJ, Singer JW, Sanders JE. Nemunaitis JJ, et al. Bone Marrow Transplant. 1991;7 Suppl 3:24-7. Bone Marrow Transplant. 1991. PMID: 1855082 Review.